I have mentioned before that I am as happy as anyone to see
I have mentioned before that I am as happy as anyone to see a green tape of trades and today’s .064 increase or 71% is exciting on record volume of 8.631M shares.
It is logical that demand for IPIX shares is increasing as new investors are discovering IPIX as a possible treatment for the coronavirus. As stated by AlanC: “The long term benefits from this will be hard to measure but the company is getting millions of dollars of free press.” The value proposition for owning IPIX prior to last week was strong based on the Brilacidin franchise with a phase 3 ready B-OM, a successful B-IBD Oral study that would fill a major need in a soon to be $48B market, a partnership with Alfasigma for UP/UPS, a phase 2 completed ABSSSI and numerous other potential applications. IPIX also has a potential blockbuster cancer drug with Kevetrin which could be a major life saving drug in over 50% of all cancer types.
Then last week the out-of-nowhere announcement and subsequent PRs have IPIX being considered as a viable treatment for the coronavirus. If the US government agencies discover that Brilacidin is a good fit for treatment of the coronavirus, we can only imagine what the tremendous upside it would present for IPIX investors. The government would demand large volumes of Brilacidin to stockpile and dozens of other countries would get in line and follow suit. IPIX would get valuable grant money and DIRECT revenue (as in 100% of sales vs a royalty fee). Criminal control over IPIX share price would change instantly.
I have also mentioned that volume is made up of transactions that have 2 components, a buyer AND a seller. A question I would throw out to all Long Term Investors that read this board is “How many of you sold IPIX shares today at the .09 to .16 range? Crickets…….. The answer is obviously none. Dugh! Why would any investor that knows the tremendous value and upside of IPIX consider selling ANY of their position at these ridiculously artificially compressed prices? (Remember the 150M to 14M Yes votes to approve increasing the Authorized Shares which was a major proof point that the vast majority of IPIX investors believe in IPIX strategy and long term value.) So where did the supply for the 8.63M shares traded today come from? The criminal underlings would suggest it must be the MFO and they used to blame Aspire as the culprit. None of us know if or how much the MFO is selling of their IPIX position. There are some traders of IPIX that may have bought at 6 or 7 cents and sold today between 9 and 16 cents but IMO this represents a very small percentage of the 8.6M shares traded. The answer is that a large majority of volume is fake.
AlanC has posted the daily FINRA numbers for years now. IMO the daily numbers are a small piece of a much larger picture of criminal manipulation. When you look at the last several trading days these percentages were 88%, 73%, 77%, 81%, 83%, 66% and 72% or an average of 77% over those 7 trading days which were all fairly high volume trading days after the coronavirus PR’s were first announced. An average guestimate of fake volume on a criminally manipulated stock is around 80% which is within a rounding error of the 77% FINRA number. Using these percentages we could guestimate today’s true volume to be somewhere in the 1.5M to 1.8M of REAL or LEGIT shares traded out of the reported 8.63M. My guess is at least half of that volume is manipulated using Naked Short Selling (NSS) as the criminals continue to dig a deeper hole for themselves.
My point is that we should appreciate the upswing days in IPIX share price but remember that both the SP and the volume is not what it appears to be. The criminals control IPIX SP and volume in the short term. At some point they will not be able to. NR needs REAL SHARES from REAL INVESTORS to cover their Naked position. IMO NR may run IPIX SP up in hopes of shorting it back down. They will do this in hopes of shaking loose some IPIX shares from Longs and traders. A major partnership for B-OM or B-IBD Oral would spoil their plan. A federal grant and government Brilacidin order would destroy NR and this could occur without a warning in the coming weeks.
This is a very exciting time to be Long IPIX. IMO we shouldn’t sell ANY of our shares cheaply to the criminals and we probably shouldn’t get overly excited about a manipulated IPIX SP based mostly on fake volume. When real demand takes place in consecutive trading days and weeks we will see IPIX SP gap up accompanied by multiple consecutive high volume days like we experienced today. IPIX SP will be in the dollars and not in the pennies once we get rolling and take back control of our company.
18
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
A compressor’s ugliest invoice is rarely the one from the service technician. It is the one nobody sees at first: a stalled production line, missed output, overtime, wasted electricity, and a maintenance crew chasing the same machine again next month. Pam Mahood of Waterloo, Iowa-based Compressed Air & Equipment Co. puts the decision where it belongs—not on the price...
Continue Reading
A locked casino floor is supposed to make secrets expensive. That is why the pitch behind ROSENBLATT lands with a little more weight than the usual Vegas chest-thumping: the coming memoir says Darryl Rosenblatt became a million-dollar gambler while using none of his own money, and that casino operators did not grasp the full shape of what had happened for years. Take a...
Continue Reading
GPU racks are easy to admire when the lights are on; keeping them useful at 3 a.m. is where the bruises show. KONST arrived at SC26 in Chicago with a sensible pitch for an AI-infrastructure market that is getting less impressed by shiny hardware lists and more obsessed with whether the thing actually works. Its theme, “24/7 GPUs Delivered in Asia,” puts the emphasis...
Continue Reading
Thirty-eight million dollars landing in one day is no small civic heartbeat. Minnesota’s Give to the Max Day brought in a record $38.4 million in 2026 for nearly 6,000 nonprofits and schools, edging past the $37.8 million raised in 2025. More than 65,000 people gave. That deserves a clear-eyed nod, not a cynical shrug. Still, the number carries two messages at once. It...
Continue Reading
Seventy photographs can make a pretty loud argument when the historical record has been this lopsided. The Ashley Gibson Barnett Museum of Art at Florida Southern College has brought LIFE: Six Women Photographers to Lakeland, and it deserves more than the usual polite nod given to a traveling museum show. Open since November 14, 2026, and running through March 7, 2027,...
Continue Reading
China's regulator moved faster than the calendar, and that is the one detail worth circling in red ink. Caliway Biopharmaceuticals has received authorization from the Center for Drug Evaluation under China's National Medical Products Administration to begin CBL-0102, its China study of injectable fat-reduction candidate CBL-514. For a clinical-stage company, an...
Continue Reading
Money mistakes get expensive long before anyone calls them mistakes. That is the uncomfortable point beneath Webster First Federal Credit Union CEO John Thomasian's November 20, 2026 discussion of financial literacy: plenty of young adults are entering the real financial world with a card, a loan offer, and a phone full of banking apps, but no sturdy framework for using...
Continue Reading
A supposedly clean homesite-option story has wandered into the legal weeds, and that is exactly where investors need to slow down. A shareholder class action against Millrose Properties alleges the company painted one business model for the market while pursuing a materially different one behind the curtain. That allegation has not been proven in court, and anybody...
Continue Reading
An epilepsy diagnosis can turn ordinary family routines into a maze overnight, which is why awareness work deserves more than the usual polite nod and a colored ribbon. Mediaplanet's national Epilepsy Awareness campaign, launched November 20, 2026, brings the subject into a USA TODAY print insert and related digital coverage during Epilepsy Awareness Month. That reach...
Continue Reading
Childcare’s math is brutal before anybody starts arguing over ownership. Families need dependable hours, educators deserve better pay, and operators must keep buildings safe, staffed and open without pricing working parents clean out of the market. That is why this new Tyton Partners review of multi-site providers deserves a fair look, even if nobody should mistake a...
Continue Reading
Top 5 Most Recently Viewed Articles
Introducing the EpiPlex™ Platform Alida Biosciences, known for its innovative tools in epigenomic research, has officially launched its EpiPlex™ platform. This groundbreaking technology stands out by being the first to detect and quantify multiple RNA modifications concurrently, using short-read sequencing. Alongside this platform, the company has introduced the...
Continue Reading
Kootenay Silver Welcomes Ron Miller to Its Board of Directors Kootenay Silver Inc. (TSXV: KTN) (OTCQX: KOOYF) proudly announces the appointment of Ron Miller as a new director. With over 30 years of rich experience in public accounting and the mining industry, Mr. Miller brings a wealth of expertise to the company. Previously, he was a Partner and National Leader in...
Continue Reading
Unusual Options Activity for Estee Lauder Cos Recently, a noticeable shift has occurred in the options trading landscape for Estee Lauder Cos (NYSE: EL). Our analysis has identified some significant bearish actions from prominent financial investors targeting this beauty giant. Out of a thorough review of options trading history for Estee Lauder Cos, a total of ten...
Continue Reading
Roche Introduces Groundbreaking PCR Test for Vaginitis Roche has recently launched an innovative PCR test aimed at enhancing the diagnostic accuracy for women dealing with vaginitis. This new assay, named cobas® BV/CV (Bacterial Vaginosis/Candida Vaginitis), harnesses the power of advanced molecular technology to identify specific bacteria and yeast linked to these...
Continue Reading
Regan Capital Announces Fee Reduction for Its Income Fund Regan Capital, a prominent investment firm overseeing more than $2.2 billion in assets, has made a significant announcement that is sure to capture the attention of investors. The firm revealed a fee reduction for its acclaimed Regan Total Return Income Fund, known by its ticker RCIRX. This open-ended mutual fund...
Continue Reading